Skip to main content
Premium Trial:

Request an Annual Quote

Where Are They Now?: Jan 1, 2003

Premium

Last January, TIGR head Claire Fraser graced the cover of Genome Technology. Inside, Fraser talked about how the institute had evolved over its decade-long existence into a microbial sequencing powerhouse. Since then, hubby Craig Venter started three new institutes to go along with the TIGR family and announced plans to turn TIGR’s sequencing facility into a high-quality closure workshop. (See last month’s GT for more on Venter’s vision.)

Also in last year’s issue: execs from Genaissance, Orchid, and Variagenics shared their know-how on setting up a large-scale SNP shop. Since then, though, the SNP scene has gotten significantly smaller. Genaissance cut 20 percent of its staff and appointed a new CEO, Orchid put its SNP instrument biz on the block, and Hyseq merged with the struggling Variagenics for its cash (see p. 19).

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.